Read by QxMD icon Read

Cardiovascular Research

J C Sluimer, A J H M Houben
No abstract text is available yet for this article.
February 13, 2019: Cardiovascular Research
Karla B Neves, Francisco J Rios, Robert Jones, T R Jeffry Evans, Augusto C Montezano, Rhian M Touyz
Vascular endothelial growth factor pathway inhibitors (VEGFi), used as anti-angiogenic drugs to treat cancer are associated with cardiovascular toxicities through unknown molecular mechanisms. Endothelial cell-derived microparticles (ECMPs) are biomarkers of endothelial injury and are also functionally active since they influence downstream target cell signaling and function. We questioned whether microparticle (MP) status is altered in cancer patients treated with VEGFi and whether they influence endothelial cell function associated with vascular dysfunction...
February 11, 2019: Cardiovascular Research
Jinxuan Zhao, Xueling Li, Jiaxin Hu, Fu Chen, Shuaihua Qiao, Xuan Sun, Ling Gao, Jun Xie, Biao Xu
Aims: Mesenchymal stem cells (MSCs) gradually become attractive candidates for cardiac inflammation modulation, yet understanding of the mechanism remains elusive. Strikingly, recent studies indicated that exosomes secreted by MSCs might be a novel mechanism for the beneficial effect of MSCs transplantation after myocardial infarction. We therefore explored the role of MSC-derived exosomes (MSC-Exo) in the immunomodulation of macrophages after myocardial ischemia/reperfusion (I/R) and its implications in cardiac injury repair...
February 8, 2019: Cardiovascular Research
Albano C Meli, Ottavio Alfieri
No abstract text is available yet for this article.
February 8, 2019: Cardiovascular Research
Quang T Nguyen, Mohamed Jalloul Nsaibia, Martin G Sirois, Angelino Calderone, Jean-Claude Tardif, Yan Fen Shi, Matthieu Ruiz, Caroline Daneault, Lyne Gagnon, Brigitte Grouix, Pierre Laurin, Jocelyn Dupuis
Aims: Heart failure with reduced ejection fraction (HFrEF) causes lung remodelling with myofibroblasts proliferation and fibrosis leading to a restrictive lung syndrome with pulmonary hypertension (PH) and right ventricular (RV) dysfunction. PBI-4050 is a first-in-class anti-fibrotic, anti-inflammatory and anti-proliferative compound. The present study evaluated the therapeutic impact of PBI-4050 on PH in an HFrEF model. Methods and Results: HFrEF was induced after myocardial infarction (MI) in rats...
February 7, 2019: Cardiovascular Research
Peter Lee, Jorge G Quintanilla, José M Alfonso-Almazán, Carlos Galán-Arriola, Ping Yan, Javier Sánchez-González, Nicasio Pérez-Castellano, Julián Pérez-Villacastín, Borja Ibañez, Leslie M Loew, David Filgueiras-Rama
Aims: Cardiac optical mapping is the gold standard for measuring complex electrophysiology in ex-vivo heart preparations. However, new methods for optical mapping in-vivo have been elusive. We aimed at developing and validating an experimental method for performing in-vivo cardiac optical mapping in pig models. Methods and Results: First, we characterized ex-vivo the excitation-ratiometric properties during pacing and ventricular fibrillation of two near-infrared voltage-sensitive dyes (di-4-ANBDQBS/di-4-ANEQ(F)PTEA) optimized for imaging blood-perfused tissue (n = 7)...
February 7, 2019: Cardiovascular Research
Jyoti Patel, Anke Smits
No abstract text is available yet for this article.
February 6, 2019: Cardiovascular Research
Ileana Badi
No abstract text is available yet for this article.
February 6, 2019: Cardiovascular Research
Inbar Raber, Aarti Asnani
Anthracyclines are a class of antineoplastic agents that remain critical to modern-day cancer treatment. However, their propensity to cause cardiotoxic effects limits their use and can cause increased morbidity and mortality among patients with cancer. Currently available methods to minimize the impact of anthracycline cardiotoxicity have not been widely successful. While it is largely accepted that the generation of oxygen radicals contributes to the development of anthracycline cardiotoxicity, the exact mechanisms of cardiomyocyte injury remain unclear...
February 6, 2019: Cardiovascular Research
Jorie Versmissen, Katrina M Mirabito Colafella, Stijn L W Koolen, A H Jan Danser
No abstract text is available yet for this article.
February 6, 2019: Cardiovascular Research
Wei-Ju Liao, Meng-Ying Wu, Chen-Chung Peng, Yi-Chung Tung, Ruey-Bing Yang
Aims: SCUBE1 (signal peptide-CUB-EGF domain-containing protein 1), expressed in endothelial cells (ECs) and platelets, exists in soluble or membrane forms. We previously showed that soluble SCUBE1 is a biomarker for platelet activation and also an active participant of thrombosis. However, whether the adhesive module of its EGF-like repeats is essential and the specific contribution of SCUBE1 synthesized in ECs or platelets to thrombosis in vivo remain unclear. Methods and Results: We generated new mutant (∆2) mice lacking the entire EGF-like repeats to evaluate the module's functional importance during thrombogenesis in vivo...
February 5, 2019: Cardiovascular Research
Youssef A Elnabawi, Amit K Dey, Aditya Goyal, Jacob W Groenendyk, Jonathan H Chung, Agastya D Belur, Justin Rodante, Charlotte L Harrington, Heather L Teague, Yvonne Baumer, Andrew Keel, Martin P Playford, Veit Sandfort, Marcus Y Chen, Benjamin Lockshin, Joel M Gelfand, David A Bluemke, Nehal N Mehta
Aims: The use of biologic therapy has increased over the past decade well beyond primary autoimmune diseases. Indeed, a recent trial using an anti-IL-1beta antibody reduced second myocardial infarction (MI) in those who have had MI. Psoriasis is a chronic inflammatory disease often treated with biologics when severe, is associated with increased risk of MI, in part driven by high-risk coronary plaque phenotypes by coronary computed tomography angiography (CCTA). We hypothesized that we would observe a reduction in inflammatory-driven phenotypes of coronary plaque, including non-calcified coronary plaque burden and lipid-rich necrotic core in those treated with biologic therapy after one-year compared with non-biologic therapy...
February 5, 2019: Cardiovascular Research
Nir Grabie, Andrew H Lichtman, Robert Padera
T lymphocyte-mediated immune responses in the heart are potentially dangerous because they can interfere with the electromechanical function. Furthermore, the myocardium has limited regenerative capacity to repair damage caused by effector T cells. Myocardial T cell responses are normally suppressed by multiple mechanisms of central and peripheral tolerance. T cell inhibitory molecules, so called immune checkpoints, limit the activation and effector function of heart-antigen reactive T cells that escape deletion during development in the thymus...
February 5, 2019: Cardiovascular Research
Zhao Li, Vineet Agrawal, Mohun Ramratnam, Ravi K Sharma, Stephen D'Auria, Abigail Sincoular, Margurite Jakubiak, Meredith L Music, William J Kutschke, Xueyin N Huang, Lindsey Gifford, Ferhaan Ahmad
Aims: We previously reported that sodium-dependent glucose cotransporter 1 (SGLT1) is highly expressed in cardiomyocytes, and is further upregulated in ischemia. This study aimed to determine the mechanisms by which SGLT1 contributes to ischemia/reperfusion (I/R) injury. Methods and Results: Mice with cardiomyocyte-specific knockdown of SGLT1 (TGSGLT1-DOWN) and wildtype controls were studied. In vivo, the LAD coronary artery was ligated for 30 min and reperfused for 48 h...
February 4, 2019: Cardiovascular Research
Wouter C Meijers, Rudolf A de Boer
Cardiovascular (CV) disease and cancer are the leading causes of death.1,2 Over the last decades, it has been appreciated that both CV disease and cancer are more common in individuals in whom risk factors for disease development accumulate, and preventative measures have been extremely important in driving down the incidence of disease.3-6 In general, the field of epidemiology, risk reduction, and preventative trials is divided into health care professionals who have an interest in either CV disease or cancer...
February 4, 2019: Cardiovascular Research
Maria T K Zaldivia, Dagmara Hering, Petra Marusic, Yusuke Sata, Rebecca Lee, Murray D Esler, Nay M Htun, Jacqueline Duval, Louise Hammond, Ulrike Flierl, Xiaowei Wang, Grant R Drummond, Antony Walton, Elizabeth E Gardiner, Robert K Andrews, Markus P Schlaich, Karlheinz Peter
Aims: To determine whether renal denervation (RDN) in hypertensive patients affects the platelet activation status. Methods and Results: We investigated the effect of RDN on the platelet activation status in 41 hypertensive patients undergoing RDN. Ambulatory blood pressure (BP), plasma sympathetic neurotransmitter Neuropeptide Y, and platelet activation markers were measured at baseline, at 3 months, and 6 months after RDN. RDN significantly decreased BP at 3 months (150...
February 4, 2019: Cardiovascular Research
Jiun-Ruey Hu, Roberta Florido, Evan J Lipson, Jarushka Naidoo, Reza Ardehali, Carlo G Tocchetti, Robert Padera, Douglas B Johnson, Javid Moslehi
Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been reported in case series but have been underappreciated due to difficulties in diagnosis and non-specific clinical manifestations. ICIs are antibodies that block negative regulators of the T cell immune response, including cytotoxic T-lymphocyte associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD-1 ligand (PD-L1). While ICIs have introduced a significant mortality benefit in several cancer types, the augmented immune response has led to a range of immune-related toxicities, including cardiovascular toxicity...
February 2, 2019: Cardiovascular Research
Majid Nikpay, Kaitlyn Beehler, Armand Valsesia, Jorg Hager, Mary-Ellen Harper, Robert Dent, Ruth McPherson
Aims: To identify genetic variants that have a regulatory impact on circulating miRNAs and to connect genetic risk to blood traits/biomarkers through the circulating miRNAs. Methods and results: Leveraging miRNA-Seq data and the 1000 Genomes imputed genotypes, we carried out genome wide association analysis for SNPs that regulate the expression of circulating miRNAs in a sample of 710 unrelated subjects of European ancestry. Wherever possible, we used data from the Framingham and the Geuvadis studies to replicate our findings...
January 31, 2019: Cardiovascular Research
Masao Endoh
No abstract text is available yet for this article.
January 31, 2019: Cardiovascular Research
Andrew G Woodman, Richard Mah, Danae L Keddie, Ronan M N Noble, Claudia D Holody, Sareh Panahi, Ferrante S Gragasin, Helene Lemieux, Stephane L Bourque
Aims: Perinatal iron deficiency alters developmental trajectories of offspring, predisposing them to cardiovascular dysfunction in later life. The mechanisms underlying this long-term programming of renal function have not been defined. We hypothesized perinatal iron deficiency causes hypertension and alters kidney metabolic function and morphology in a sex-dependent manner in adult offspring. Furthermore, we hypothesized these effects are exacerbated by chronic consumption of a high salt diet...
January 31, 2019: Cardiovascular Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"